Matches in SemOpenAlex for { <https://semopenalex.org/work/W119432023> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W119432023 endingPage "90" @default.
- W119432023 startingPage "85" @default.
- W119432023 abstract "To compare the efficacy and safety of oral granisetron hydrochloride tablets with that of oral prochlorperazine sustained-release capsules in preventing nausea and emesis induced by moderately emetogenic chemotherapeutic agents.In this multicenter, double-blind, randomized, parallel group study, oral granisetron and oral prochlorperazine were compared in 230 chemotherapy-naive, adult cancer patients who received moderately emetogenic chemotherapy. Patients were stratified by gender and randomized to receive either 1.0 mg oral granisetron HCI twice a day for 7 days, or 10 mg oral prochlorperazine sustained-release capsules twice a day for 7 days. The first dose was given 1 hour before initiation of chemotherapy and the second dose 12 hours after the first dose. Patients were evaluated for emetic episodes, extent of nausea, and adverse events for 7 days after the start of chemotherapy. Primary efficacy parameters were complete response (no emetic episodes, no greater than mild nausea, no antiemetic rescue) and total control (no emetic episodes, no nausea, no antiemetic rescue) in the 24 hours after the start of chemotherapy.Granisetron was significantly more effective than prochlorperazine in achieving a complete response (74% vs. 41%, respectively) and total control of nausea and vomiting (58% vs. 33%, respectively) at the 24-hour assessment. Complete response at 24 hours was significantly higher in the granisetron-treated patients than in prochlorperazine-treated patients. In women, granisetron showed a complete response rate of 69% versus 38% with prochlorperazine; in men, granisetron showed a complete response rate of 92% versus 61% with prochlorperazine. Both regimens were well tolerated, with headache (36% for granisetron, 29% for prochlorperazine) and constipation (31% for granisetron, 6% for prochlorperazine) the most common adverse events.: Oral granisetron 1 mg twice a day was significantly more effective than oral prochlorperazine sustained release capsules 10 mg twice a day in complete response and total control of nausea and vomiting at 24 hours after chemotherapy. Both agents were well tolerated." @default.
- W119432023 created "2016-06-24" @default.
- W119432023 creator A5021898672 @default.
- W119432023 creator A5037398995 @default.
- W119432023 creator A5054399119 @default.
- W119432023 creator A5057536882 @default.
- W119432023 creator A5059207909 @default.
- W119432023 creator A5064097562 @default.
- W119432023 creator A5072308451 @default.
- W119432023 date "1996-03-01" @default.
- W119432023 modified "2023-09-26" @default.
- W119432023 title "Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy." @default.
- W119432023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9166505" @default.
- W119432023 hasPublicationYear "1996" @default.
- W119432023 type Work @default.
- W119432023 sameAs 119432023 @default.
- W119432023 citedByCount "3" @default.
- W119432023 crossrefType "journal-article" @default.
- W119432023 hasAuthorship W119432023A5021898672 @default.
- W119432023 hasAuthorship W119432023A5037398995 @default.
- W119432023 hasAuthorship W119432023A5054399119 @default.
- W119432023 hasAuthorship W119432023A5057536882 @default.
- W119432023 hasAuthorship W119432023A5059207909 @default.
- W119432023 hasAuthorship W119432023A5064097562 @default.
- W119432023 hasAuthorship W119432023A5072308451 @default.
- W119432023 hasConcept C126322002 @default.
- W119432023 hasConcept C141071460 @default.
- W119432023 hasConcept C197934379 @default.
- W119432023 hasConcept C2776694085 @default.
- W119432023 hasConcept C2777452722 @default.
- W119432023 hasConcept C2780580376 @default.
- W119432023 hasConcept C2780852908 @default.
- W119432023 hasConcept C2780884295 @default.
- W119432023 hasConcept C2781324269 @default.
- W119432023 hasConcept C42219234 @default.
- W119432023 hasConcept C71924100 @default.
- W119432023 hasConceptScore W119432023C126322002 @default.
- W119432023 hasConceptScore W119432023C141071460 @default.
- W119432023 hasConceptScore W119432023C197934379 @default.
- W119432023 hasConceptScore W119432023C2776694085 @default.
- W119432023 hasConceptScore W119432023C2777452722 @default.
- W119432023 hasConceptScore W119432023C2780580376 @default.
- W119432023 hasConceptScore W119432023C2780852908 @default.
- W119432023 hasConceptScore W119432023C2780884295 @default.
- W119432023 hasConceptScore W119432023C2781324269 @default.
- W119432023 hasConceptScore W119432023C42219234 @default.
- W119432023 hasConceptScore W119432023C71924100 @default.
- W119432023 hasIssue "2" @default.
- W119432023 hasLocation W1194320231 @default.
- W119432023 hasOpenAccess W119432023 @default.
- W119432023 hasPrimaryLocation W1194320231 @default.
- W119432023 hasRelatedWork W119432023 @default.
- W119432023 hasRelatedWork W1537122182 @default.
- W119432023 hasRelatedWork W2001374639 @default.
- W119432023 hasRelatedWork W2022077452 @default.
- W119432023 hasRelatedWork W2034199439 @default.
- W119432023 hasRelatedWork W2074431992 @default.
- W119432023 hasRelatedWork W2138524596 @default.
- W119432023 hasRelatedWork W2145895094 @default.
- W119432023 hasRelatedWork W2348573567 @default.
- W119432023 hasRelatedWork W2460534820 @default.
- W119432023 hasVolume "2" @default.
- W119432023 isParatext "false" @default.
- W119432023 isRetracted "false" @default.
- W119432023 magId "119432023" @default.
- W119432023 workType "article" @default.